Drug Profile


Alternative Names: Anti-CD22 monoclonal antibody LL2 Tc 99m; ImmuRAID LL2 Tc 99m; LymphoScan

Latest Information Update: 24 Jun 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunomedics
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceutical diagnostics
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma

Most Recent Events

  • 18 Sep 2003 Suspended - Phase-III for Non-Hodgkin's lymphoma (diagnosis) in European Union (IV)
  • 18 Sep 2003 Suspended - Phase-III for Non-Hodgkin's lymphoma (diagnosis) in USA (IV)
  • 11 Sep 2001 The US FDA has designated orphan drug status to Bectumomab for lymphoma diagnosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top